...
首页> 外文期刊>BMC Psychiatry >Continue, adjust, or stop antipsychotic medication: developing and user testing an encounter decision aid for people with first-episode and long-term psychosis
【24h】

Continue, adjust, or stop antipsychotic medication: developing and user testing an encounter decision aid for people with first-episode and long-term psychosis

机译:继续,调整或停止抗精神病药物:为初发和长期精神病患者开发和测试相遇决策辅助工具

获取原文
   

获取外文期刊封面封底 >>

       

摘要

People with psychosis struggle with decisions about their use of antipsychotics. They often want to reduce the dose or stop, while facing uncertainty regarding the effects these decisions will have on their treatment and recovery. They may also fear raising this issue with clinicians. The purpose of this study was to develop and test a?shared decision making (SDM) tool to support patients and clinicians in making decisions about antipsychotics. A diverse editorial research team developed an Encounter Decision Aid (EDA) for patients and clinicians to use as part of the psychiatric consultation. The EDA was tested using 24 semistructured interviews with participants representing six stakeholder groups: patients with first-episode psychosis, patients with long-term psychosis, family members, psychiatrists, mental health counselors, and administrators. We used inductive and deductive coding of interview transcripts to identify points to revise within three domains: general impression and purpose of the EDA; suggested changes to the content, wording, and appearance; and usability and potential contribution to the psychiatric consultation. An EDA was developed in an iterative process that yielded evidence-based answers to five frequently asked questions about antipsychotic medications. Patients with long-term psychosis and mental health counselors suggested more changes and revisions than patients with first-episode psychosis and psychiatrists. Family members suggested more revisions to the answers about potential risks of stopping or adjusting antipsychotics than other respondents. The EDA was perceived as potentially useful and feasible in psychiatric routine care, especially if presented during the consultation.
机译:患有精神病的人在使用抗精神病药的决定上挣扎。他们常常想减少剂量或停止服用,同时在不确定这些决定对他们的治疗和康复的影响方面面临不确定性。他们可能还担心会向临床医生提出这个问题。这项研究的目的是开发和测试共享决策制定(SDM)工具,以支持患者和临床医生就抗精神病药物做出决策。多样化的编辑研究团队开发了针对患者和临床医生的遭遇决策援助(EDA),作为精神病咨询的一部分。使用24个半结构化访谈对EDA进行了测试,代表六个利益相关者群体的参与者进行了访谈:初发精神病患者,长期精神病患者,家庭成员,精神病医生,心理健康顾问和管理人员。我们使用访谈记录的归纳和演绎编码来确定要在三个领域内进行修改的点:EDA的总体印象和目的;建议对内容,措辞和外观进行更改;可用性以及对精神科咨询的潜在贡献。 EDA是通过迭代过程开发的,它为有关抗精神病药物的五个常见问题提供了循证答案。长期精神病患者和心理健康咨询师建议的变化和修正要多于首次发作的精神病患者和精神病医生。家庭成员建议对其他有关停止或调整抗精神病药潜在风险的答案进行更多的修订。 EDA被认为在精神科常规护理中可能有用且可行,尤其是在咨询过程中提出的情况下。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号